Asthma pill for kids shows promise in early trial

NCT ID NCT03650400

Terminated Symptom relief Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at how a new chewable asthma tablet called fevipiprant works in children aged 6 to 12. The goal was to measure the drug's levels in the body and check for safety. Only 11 children took part before the study was stopped early.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ASTHMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

asthma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ASTHMA

Contacts and locations

Locations

Novartis Investigative Site

Minneapolis, Minnesota, 55402, United States
Novartis Investigative Site

Columbia, Missouri, 65203, United States
Novartis Investigative Site

Tulsa, Oklahoma, 74136, United States
Novartis Investigative Site

Boerne, Texas, 78006, United States
Novartis Investigative Site

El Paso, Texas, 79903, United States
Novartis Investigative Site

San Antonio, Texas, 78229, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.